Bluetongue virus structural components

Development of a Competitive Enzyme-Linked Immunosorbent Assay Based on Purified Recombinant Viral Protein 7 for Serological Diagnosis of Epizootic Haemorrhagic Disease in Camels

Epizootic haemorrhagic disease virus (EHDV) is a member of the Orbivirus genus in the Reoviridae family, and it is the etiological agent of an arthropod-transmitted disease that affects domestic and wild ruminants. Due to its significant economic impact, many attempts have been done in order to develop diagnostic immunoassays mainly based on the use of the viral protein 7 (VP7), that is, the immunodominant serogroup-specific antigen. In this work, a recombinant VP7 (recVP7) of EHDV serotype 2 was produced in a baculovirus system, and after purification using ion metal affinity chromatography, we obtained a high yield of recombinant protein characterized by a high degree of purity. We used the purified recVP7 as reagent to develop a competitive enzyme-linked immunoassay (c-ELISA), and we tested the presence of EHDV antibodies in 185 dromedary camel serum samples. The c-ELISA showed good performance parameters in recognising positive sera of naturally EHDV-infected dromedary camels; in particular, our developed test reached 85.7% of sensitivity, 98.1% of specificity, 93% of accuracy, and a high agreement value with results obtained by the commercial ELISA kit (Cohen's kappa value of 0.85) that we adopted as the reference method. This c-ELISA could be a useful screening test to monitor the virus spread in camels that are sentinel animals for endemic areas of disease.

Ovine and murine T cell epitopes from the non-structural protein 1 (NS1) of bluetongue virus serotype 8 (BTV-8) are shared among viral serotypes

Bluetongue virus (BTV) is a non-enveloped dsRNA virus that causes a haemorrhagic disease mainly in sheep. It is an economically important Orbivirus of the Reoviridae family. In order to estimate the importance of T cell responses during BTV infection, it is essential to identify the epitopes targeted by the immune system. In the present work, we selected potential T cell epitopes (3 MHC-class II-binding and 8 MHC-class I binding peptides) for the C57BL/6 mouse strain from the BTV-8 non-structural protein NS1, using H2^b-binding predictive algorithms. Peptide binding assays confirmed all MHC-class I predicted peptides bound MHC-class I molecules. The immunogenicity of these 11 predicted peptides was then determined using splenocytes from BTV-8-inoculated C57BL/6 mice. Four MHC-class I binding peptides elicited specific IFN-γ production and generated cytotoxic T lymphocytes (CTL) in BTV-8 infected mice. CTL specific for 2 of these peptides were also able to recognise target cells infected with different BTV serotypes. Similarly, using a combination of IFN-γ ELISPOT, intracellular cytokine staining and proliferation assays, two MHC-class II peptides were identified as CD4⁺ T cell epitopes in BTV-8 infected mice. Importantly, two peptides were also consistently immunogenic in sheep infected with BTV-8 using IFN-γ ELISPOT assays. Both of these peptides stimulated CD4⁺ T cells that cross-reacted with other BTV serotypes. The characterisation of these T cell epitopes can help develop vaccines protecting against a broad spectrum of BTV serotypes and differentiate infected from vaccinated animals.

History of Orbivirus research in South Africa

In the early colonial history of South Africa, horses played an important role, both in general transportation and in military operations. Frequent epidemics of African horsesickness (AHS) in the 18th century therefore severely affected the economy. The first scientific research on the disease was carried out by Alexander Edington (1892), the first government bacteriologist of the Cape Colony, who resolved the existing confusion that reigned and established its identity as a separate disease. Bluetongue (BT) was described for the first time by Duncan Hutcheon in 1880, although it was probably always endemic in wild ruminants and only became a problem when highly susceptible Merino sheep were introduced to the Cape in the late 18th century. The filterability of the AHS virus (AHSV) was demonstrated in 1900 by M'Fadyean in London, and that of the BT virus (BTV) in 1905 by Theiler at Onderstepoort, thus proving the viral nature of both agents. Theiler developed the first vaccines for both diseases at Onderstepoort. Both vaccines consisted of infective blood followed by hyper-immune serum, and were used for many years. Subsequent breakthroughs include the adaptation to propagation and attenuation in embryonated eggs in the case of BTV and in mouse brains for AHSV. This was followed by the discovery of multiple serotypes of both viruses, the transmission of both by Culicoides midges and their eventual replication in cell cultures. Molecular studies led to the discovery of the segmented double-stranded RNA genomes, thus proving their genetic relationship and leading to their classification in a genus called Orbivirus. Further work included the molecular cloning of the genes of all the serotypes of both viruses and clarification of their relationship to the viral proteins, which led to much improved diagnostic techniques and eventually to the development of a recombinant vaccine, which unfortunately has so far been unsuitable for mass production.

Bluetongue virus (BTV): propagation, quantification, and storage

As an obligate intracellular parasite, the genome of the Bluetongue virus (BTV) contains ten double-stranded RNA segments which are encapsidated by viral proteins, forming "transport vesicles" that can transmit the viral progeny cell-to-cell efficiently and that can also be transmitted animal-to-animal by a biting midge. BTV is a cytoplasmic virus, and its five major steps of viral infection: attachment, entry, uncoating, assembly, and release, occur only in the cytosol within the infected host cell. Viral replication, suppression of cellular processes, and subsequent pathological damage disrupt many cellular pathways, leading to cellular apoptosis. All of these steps are under very rapid, tight, and efficient control. BTV infects both domestic and wild ruminants, especially sheep, but not humans. BTV is also the prototype in the Orbivirus genus of the Reoviridae family, and has been studied very extensively for the last 25 years. The experimental protocols presented here describe most of the methods that have been used routinely and reproducibly in our lab for our studies of the BTV biosystems.

Oncolytic bluetongue viruses: promise, progress, and perspectives

Humans are sero-negative toward bluetongue viruses (BTVs) since BTVs do not infect normal human cells. Infection and selective degradation of several human cancer cell lines but not normal ones by five US BTV serotypes have been investigated. We determined the susceptibilities of many normal and human cancer cells to BTV infections and made comparative kinetic analyses of their cytopathic effects, survival rates, ultra-structural changes, cellular apoptosis and necrosis, cell cycle arrest, cytokine profiles, viral genome, mRNAs, and progeny titers. The wild-type US BTVs, without any genetic modifications, could preferentially infect and degrade several types of human cancer cells but not normal cells. Their selective and preferential BTV-degradation of human cancer cells is viral dose–dependent, leading to effective viral replication, and induced apoptosis. Xenograft tumors in mice were substantially reduced by a single intratumoral BTV injection in initial in vivo experiments. Thus, wild-type BTVs, without genetic modifications, have oncolytic potentials. They represent an attractive, next generation of oncolytic viral approach for potential human cancer therapy combined with current anti-cancer agents and irradiation.

Biological mimicry of the bluetongue virus core protein VP7 by rabbit anti-idiotype

A subpopulation of rabbit polyclonal anti-idiotypic antibody (anti-Id) was previously produced to a murine monoclonal antibody (mAb) (M1875) specific for the bluetongue virus core protein VP7. In this report, mimicry of VP7 by this anti-Id (designated RAb2-A) was functionally analyzed through immunization of Balb/c mice with RAb2-A or purified VP7. Animals immunized with RAb2-A were able to produce an M1875-like Ab3 antibody response with idiotype and epitope specificity resembling that of M1875 without subsequent exposure to the nominal antigen. This conclusion was supported by experiments showing that the RAb2-A-induced Ab3 antibodies (i) reacted specifically with the immunizing anti-Id; (ii) were capable of binding VP7; (iii) inhibited M1875 from binding to VP7; and (iv) inhibited M1875 from binding to RAb2-A. Similarly, mice immunized with purified VP7 also produced antibodies that exhibited characteristics such as idiotype and epitope specificity in common with M1875. No antibody response to VP7 was detected in control groups of mice immunized with either normal rabbit IgG or BHK-21 cell components. Therefore, it can be concluded that rabbit anti-Id RAb-2-A mimics an M1875-defined VP7 epitope sufficiently to function as a surrogate antigen for inducing an anti-bluetongue virus response.

Evidence that two distinct populations of rabbit anti-idiotypic antibodies are induced by three monoclonal antibodies specific for bluetongue virus core protein VP7

Three groups of anti-idiotypic antibodies (anti-Id or Ab2), designated RAb2-A, RAb2-B1, and RAb2-B2, were isolated from rabbit antiserum raised against three monoclonal antibodies (mAbs) (M1875, M1877, and M1886) specific for the bluetongue virus core protein, VP7. RAb2-A was specific for the idiotype of M1875. RAb2-B1 and RAb2-B2, isolated through the M1877 and M1886 affinity columns, respectively, were directed against the common idiotype that is shared by M1877 and M1886 and therefore classified in the same population (RAb2-B). Further characterization revealed that the two anti-Id populations, RAb2-A and RAb2-B, were significantly different. RAb2-A was an Ab2 beta type of anti-Id since (i) its reaction with M1875 was inhibited by the antigen; (ii) it inhibited the M1875-VP7 interaction; and (iii) it elicited anti-VP7 antibody response in Balb/c mice. In contrast, RAb2-B may represent an Ab2 alpha type of anti-Id since its reactions with M1877 or M1886 were not inhibited by the antigen, even though it inhibited mAbs from binding to the antigen. These results indicated that RAb2-A and RAb2-B represent two distinct populations of anti-Ids to anti-VP7 mAbs with similar epitope specificity.

Internal image rabbit anti-idiotypic antibody detects sheep antibodies to the bluetongue virus core protein VP7

BACKGROUND

Rabbit polyclonal anti-idiotypic antibodies (anti-Id) were generated against three murine monoclonal antibodies (MAbs) specific for the group-specific antigen VP7 of bluetongue virus (BTV) by the sequential immunization method. It was demonstrated by serological tests that part of the anti-Id possesses the characteristics of internal image anti-Id. By affinity purification against the individual MAbs, the internal image anti-Id, designated RAb2-A, was isolated and identified as specific for the MAb, M1875.

OBJECTIVES

To examine the ability of RAb2-A to detect sheep anti-VP7 antibodies by recognition of the common idiotype (Idx).

STUDY DESIGN

Affinity-purified RAb2-A IgG, along with VP7, was applied on the solid-phase of ELISA plate and the membrane for Western blot analysis to detect anti-VP7 antibodies from sheep that were immunized with VP7 or were experimentally infected with BTV. An inhibition ELISA was employed to determine whether sheep anti-VP7 and M1875 recognize the same or similar epitope(s).

RESULTS

RAb2-A recognised the Idx on anti-VP7 antibodies from sheep that were either immunized with VP7 or experimentally infected with BTV. Specificity of the reaction was confirmed by the observation that RAb2-A did not react with normal sheep serum or sheep antibodies against epizootic haemorrhagic disease of deer virus, a bluetongue-related disease virus in the Orbivirus genus.

CONCLUSION

The ability of RAb2-A to detect anti-VP7 antibodies through recognition of the Idx suggests that RAb2-A can be used as a probe to detect anti-BTV antibodies.

Mapping and characterization of antigenic epitopes and the nucleic acid-binding domains of the VP6 protein of bluetongue viruses

Heterologously expressed VP6 and truncated VP6 proteins of bluetongue virus (BTV) serotype 11 purified to near homogeneity were used for structure and function analyses. The yield of the expressed VP6 was host cell dependent. Six antigenic epitopes of VP6 of BTV were identified and mapped by immunoblot analyses and enzyme-linked immunosorbent assay with oligoclonal antibodies. These determinants were surface accessible and conserved among the cognate VP6 proteins of five U.S. BTV serotypes. The amino acid sequences and sizes of these six antigenic epitopes were determined, and their precise locations were also mapped and confirmed by deletion analyses. The nucleic acid binding activities of VP6, confirmed by electrophoretic mobility shift assay, were concentration dependent. The binding activities and affinities of the purified expressed VP6 protein towards double-stranded RNA and double-stranded DNA were similar. Two domains of VP6, corresponding to three of the six antigenic epitopes, were responsible for the nucleic acid binding activities and have been mapped within 28 amino acids near the middle and 11 residues near the carboxyl terminus of VP6 by electrophoretic mobility shift assay and deletion mutant analyses. Synthetic oligopeptides corresponding to these three regions also exhibited similar concentration-dependent nucleic acid binding activities.

Competitive ELISA for serodiagnosis of bluetongue: evaluation of group-specific monoclonal antibodies and expressed VP7 antigen

The performance of 2 competitive enzyme-linked immunosorbent assays (C-ELISA) was compared with the reference C-ELISA I for the detection of antibodies to bluetongue virus (BTV). One of the assays (C-ELISA II) used a group-specific monoclonal antibody (MAb) to BTV, obtained from the American Type Culture Collection (8A3B-6) and tissue culture (TC)-derived BTV antigen (Ag), and the other assay (C-ELISA III) used BTV core protein VP7 (expressed in yeast) and the reference MAb (Pirbright Laboratory, 3-17-A3). Test sera were obtained by sequential blood samples from 22 calves, each inoculated with a different serotype (T) of BTV (South African [SA] T-1-T-16 and T-18-T-20 and USA T-11, T-13, and T-17). Sera were also obtained from 4 calves and 4 sheep inoculated with USA BTV T-10 and from several groups of calves exposed to single or multiple doses of epizootic hemorrhagic disease virus (EHDV) T-1-T-4 grown in TC (BHK-21) or suckling mouse brain (SMB). A total of 618 bovine and ovine field sera collected from BT-free and BT-endemic areas were also tested. The C-ELISA III was more sensitive than the C-ELISA II in the detection of anti-BTV antibody in sera from cattle and sheep early after infection with BTV. Seroconversion was demonstrated by the 3 C-ELISAs in all animals inoculated with BTV by 20 days postinfection (DPI), except in calves that received SA T-3 or USA T-13, which became positive at 40 DPI.(ABSTRACT TRUNCATED AT 250 WORDS)